ONA Therapeutics Strengthens Scientific Leadership Team
/PRNewswire/ -- ONA Therapeutics ("ONA"), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism in order to...
Stay updated with breaking news from Antibody Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- ONA Therapeutics ("ONA"), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism in order to...
Antibody Services Market Forecast, Revenue, Demand, Growth and Key Companies Valuation by 2028
CHICAGO, May 4, 2021 /PRNewswire/ -- According to the new market research report "Custom Antibody Market by Service (Antibody Development, Production, Labelling), Type (Monoclonal, Polyclonal
As such, an increase in research activity-especially in the life sciences industry-along with growing industry-academia collaborations are the primary growth drivers for this market. In addition, the objective behind custom antibody production is to acquire an antibody that performs well in a particular qualitative or quantitative immunodetection method. The quality of catalog antibodies (to ensure the reproducibility of results) is also an area of concern in this market, which is primarily why end users prefer custom-made antibodies. Antibody Development accounted for the largest share of cu...
Press release content from Business Wire. The AP news staff was not involved in its creation. BigHat Biosciences Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments February 10, 2021 GMT BigHat co-founders Mark DePristo and Peyton Greenside (Photo: Business Wire) SAN CARLOS, Calif.--(BUSINESS WIRE)--Feb 10, 2021-- BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody design platform, today announced it has raised $19 million in an oversubscribed Series A funding round, led by Andreesse...